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Simple Summary: Several genes have been confirmed as risk genes for epithelial ovarian cancer 
(EOC). There are five main types of EOC, with different molecular changes and clinical characteristics, 
suggesting they should be considered different diseases. This review summarises the contribution of 
rare inherited mutations to EOC susceptibility, focussing on the frequency in each EOC type. 
Susceptibility genes can have a major clinical impact, reducing ovarian cancer incidence by screening 
of family members to detect women at higher risk than the general population. They can also lead to 
the development of new targeted treatments. 
Abstract: A family history of ovarian or breast cancer is the strongest risk factor for epithelial ovarian 
cancer (EOC). Germline deleterious variants in the BRCA1 and BRCA2 genes confer EOC risks by age 
80, of 44% and 17% respectively. The mismatch repair genes, particularly MSH2 and MSH6, are also 
EOC susceptibility genes. Several other DNA repair genes, BRIP1, RAD51C, RAD51D, and PALB2, 
have been identified as moderate risk EOC genes. EOC has five main histotypes; high-grade serous 
(HGS), low-grade serous (LGS), clear cell (CCC), endometrioid (END), and mucinous (MUC). This 
review examines the current understanding of the contribution of rare genetic variants to EOC, 
focussing on providing frequency data for each histotype. We provide an overview of frequency and 
risk for pathogenic variants in the known susceptibility genes as well as other proposed genes. We 
also describe the progress to-date to understand the role of missense variants and the different breast 
and ovarian cancer risks for each gene. Identification of susceptibility genes have clinical impact by 
reducing disease-associated mortality through improving risk prediction, with the possibility of 
prevention strategies, and developing new targeted treatments and these clinical implications are also 
discussed. 
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1. Introduction 
Epithelial ovarian cancer (EOC) is the seventh most common cancer in women worldwide, with 
over 295,000 incident cases each year, and is the leading cause of mortality relating to gynaecological 
malignancies, with 184,000 deaths each year [1]. Typically, EOCs are stratified into five main 
histological subtypes: High grade serous, which account for up to 70% of all EOC cases, endometrioid 
(~10%), clear cell (~10%), mucinous (~3%), and low-grade serous carcinomas (<5%) [2]. The five different 
histotypes have different risk factors and molecular characteristics. The inherited genetics of each 
histotype is also likely to be different. 
The prognosis of ovarian cancer is poor, with a five-year survival rate of just 47% [3]. Ovarian 
cancer is difficult to diagnose early in its disease course, and 80% of cases are diagnosed after extensive 
metastasis at stage III or IV, which carry a five-year survival rate of 41% and 20% respectively [3]. 
However, outcomes are good if ovarian cancer is detected early, with an 89% five-year survival in stage 
I cancers [3]. Screening for ovarian cancer is of limited utility and no studies investigating ovarian 
cancer screening have shown a significant impact of screening on mortality [4,5]. As a result, 
population-based screening for ovarian cancer is not recommended in the guidelines of any major 
society. As the prognosis of EOC is related to its stage at diagnosis, the ability to use genetic information 
to predict EOC risk and intervene before disease development would reduce overall mortality and 
morbidity in ovarian cancer [6]. 
A family history of EOC confers an increase in relative risk (RR) of ovarian cancer of 2.96. The 
known EOC risk genes explain less than half of the excess familial risk for EOC, suggesting that there 
are still undiscovered ovarian cancer predisposing genes to be found [7,8]. The known ovarian cancer 
predisposing genes are from two different DNA repair pathways. The homologous recombination (HR) 
DNA repair pathway and the mismatch repair (MMR) DNA pathway. The majority of the genes are 
part of the HR DNA repair pathway. BRCA1 and BRCA2 have been confirmed as highly penetrant 
predisposition genes for EOC [9]. Several other genes—BRIP1, RAD51C, RAD51D, and PALB2, recently 
described as moderate risk genes, are also part of this pathway [10–12]. The mismatch repair genes 
MLH1, MSH2, MSH6, and PSM2 are also confirmed moderate risk EOC susceptibility genes [13]. The 
frequency of disease-associated variants in these genes is different for the different EOC histotypes. 
Thirty-seven common variants have been identified for ovarian cancer, using genome-wide association 
studies (GWAS) [14,15]. The ability to derive accurate risk estimates for ovarian cancer from genetic 
information in asymptomatic women has significant implications for ovarian cancer management. 
This review aims to summarise the progress to date in efforts to understand the contribution of 
rare genetic variants to ovarian cancer and histotype specific differences, as well as the clinical 
implications of these discoveries. In the first part of this review, we describe germline protein 
truncating variants (insertion/deletions or nonsense) in confirmed EOC susceptibility genes, followed 
by an overview of the role of missense variants in these genes. Lastly, we described germline protein 
truncating variants in other proposed genes that have not been validated as EOC susceptibility genes. 
2. Protein Truncating Variants in Confirmed Susceptibility Genes 
2.1. BRCA1 and BRCA2 
These two major breast/ovarian cancer susceptibility genes encode proteins that work in DNA 
replication pathways to avoid double-strand DNA damage. Deleterious protein truncating variants 
include small insertions and deletions and single base changes, as well as large genomic alterations, 
which account for approximately 10% of BRCA1 variants [16]. Several deleterious missense variants 
have also been described. 
The prevalence and penetrance of deleterious variants in BRCA1 and BRCA2 has been extensively 
studied in ovarian cancer patients. The case ascertainment, either from families with a history of breast 
or ovarian cancer or from the general ovarian cancer population, has a major impact on the results. The 
presence of founder mutations in the population also affects the prevalence and has important 
implications for clinical testing. The presence of founder mutations can allow for cheap and rapid 
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testing and the potential for population screening. In the Ashkenazi Jewish population, there are three 
BRCA founder mutations (185delAG and 5382insC in BRCA1 and 6174delT in BRCA2) that accounts for 
almost all mutations present in this population [17]. In the Icelandic population, there is a single 
founder mutation, 999del5, in the BRCA2 gene. Most of the breast and ovarian cancer cases in Icelandic 
families have this BRCA2 founder mutation, while mutations in BRCA1 are very rare [18]. Founder 
mutations in the BRCA genes have also been reported in many other populations, including Russians 
[19,20], Polish [21], Norwegian [22], Finnish [23], Japanese [24], and Chinese [25]. While some mutations 
are restricted to isolated regions or certain populations, others are common across different countries, 
such as BRCA1 5382insC mutation that is common in many European populations [17]. 
Early studies of cases selected for a family history of breast or ovarian cancer found that 24–76% 
had deleterious variants in BRCA1 and 1–17% had deleterious variants in BRCA2 [17]. Recent studies 
using clinical testing laboratory data have reported the prevalence of BRCA1/2 pathogenic variants in 
5020 and 7489 cases from the USA [26,27], 4409 cases from France [28], and 3230 cases from a meta-
analysis of 48 multi-gene panel testing-based studies [29]. In these studies, the frequency of germline 
pathogenic variants in BRCA1 in ovarian cancer cases were 5.1%, 3.6%, 3.7%, and 8.6%, respectively, 
and 3.9%, 3.3%, 4.0%, and 4.5% in BRCA2 [26–29]. 
Testing of unselected ovarian cancer cases in non-Ashkenazi Jewish populations shows that the 
frequency of deleterious BRCA1 and BRCA2 variants ranged from 3–10% and 0.6–6%, respectively [17]. 
Recent population-based studies from Table 1 found that 3.8–11.1% of cases have BRCA1 deleterious 
variants and 4.3–6.4% had BRCA2 deleterious variants. 
In a large prospective study of BRCA carriers ascertained through family clinics, the cumulative 
risk, by age 80, of ovarian cancer in women with pathogenic variants in BRCA1 and BRCA2 was 
estimated to be 44% (95% confidence interval (CI), 36–53%) and 17% (95% CI, 11–25%), respectively [9]. 
The histotypes of ovarian cancer diagnosed in the study were not described [9]. Breast cancer was also 
assessed and the cumulative risk at the age of 80 years was estimated to be 72% (95% CI, 65–79%) for 
BRCA1 carriers and 69% (95% CI, 61–77%) for BRCA2 [9]. Variants in these BRCA genes are also 
associated with increased risk of pancreatic cancer [30] and high-grade prostate cancer [31]. 
Four studies, with cases unselected for age or family history, provided information on histotype 
(Table 1). Due to the small numbers of the much rarer histotypes (END, CCC, LGS, and MUC), the 
frequencies of germline pathogenic variants varied significantly. In an effort to estimate the frequency 
in these rarer histotypes, we have combined the results across studies. This showed that the frequency 
of deleterious variants in BRCA1 were approximately 7.8% in HGS, 3% in END, 3.6% in CCC, 3.7% in 
LGS, and <1% in MUC [32–35]. In BRCA2, deleterious variants were seen in approximately 5.9% of HGS 
cases, 2.9% of END, 0.9% of CCC, 2.0% of LGS, and <1% of MUC [33–35] (Table 1). According to these 
data, both genes have a higher frequency of variants in the HGS histotype compared to the non-HGS 
histotypes, and a much lower frequency in mucinous cases. Available cumulative risks from these 
retrospective studies are comparable to the prospective study previously mentioned [9] (Table 1). 
Ovarian cancer patients with deleterious variants in BRCA1 and BRCA2 are characterized by 
genomic instability within their tumours. They have a better response to platinum-based 
chemotherapies, resulting in improved five-year overall survival. Five-year overall survival for non-
carriers was reported to be 36% (95% CI 34–38) compared to 44% (95% CI 40–48) for BRCA1-carriers 
and 52% (95% CI 46–58) for BRCA2-carriers [36]. However, this survival advantage was not present 
when follow-up was extended to 10 years [37,38]. 
Identifying pathogenic variants associated with increased risk of ovarian cancer has major clinical 
implications. Due to the magnitude of ovarian cancer risk associated with variants in BRCA1 and 
BRCA2, risk-reducing salpingo-oophorectomy (RRSO) is currently recommended as a prevention 
strategy for BRCA1 carriers by age 35 to 40 years, once the woman’s childbearing is complete, and for 
BRCA2 carriers by age 40 to 45 [39]. 
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Table 1. Frequency of germline pathogenic variants in BRCA1/2 in epithelial ovarian cancer (EOC) histotypes, in cases from population studies. 
Gene Study 
Cases 
Carriers/Total (Frequency) 
Controls 
Carriers/Total (Frequency) OR  
(95% CI) 
Cumulative Risk 
(95% CI) a 
HGS END CCC LGS MUC 
Mixed/ 
Unk b 
All EOC Matched Publicly Available 
BRCA1 
Walsh et al., 
2011 [34] 
31/242 ** 2/23 1/17 
** - 
6/78 40/360 
- - NC NC 
(12.8%) (8.7%) (5.9%) (7.7%) (11.1%) 
Alsop et al., 
2012 † [32] 
74/709 ** 7/119 4/63 
** - 
3/110 88/1001 
- - NC NC 
(10.4%) (5.9%) (6.3%) (2.7%) (8.79%) 
Song et al.,  
2014 ^ [33] 
58/1105 * 3/322 3/192 6/172 1/157 13/274 84/2222 1/1528 
- 
60 # 
(10–2100) 
61% 
(15–99%) (5.2%) (0.9%) (1.6%) (3.5%) (0.6%) (4.7%) (3.78%) (0.07%) 
Norquist et al., 2016 [35] 
155/1498 4/77 4/58 3/70 0/16 16/196 142/1915 
- 
114/36276 48.9 
(24–100) 
NC 
(10.3%) (5.2%) (6.9%) (4.3%) (0%) (8.2%) (7.41%) (0.31%) 
Total 
278/3554 16/541 12/330 9/242 1/173 38/658 354/5498 1/1528 
- - - 
(7.82%) (2.95%) (3.63%) (3.72%) (0.58%) (5.77%) (6.43%) (0.07%) 
BRCA2 
Walsh et al.,  
2011 [34] 
18/242 ** 0/23 0/17 
** - 
5/78 23/360 
- - NC NC 
(7.4%) (0%) (0%) (6.4%) (6.38%) 
Alsop et al., 
2012 † [32] 
44/709 ** 3/119 0/63 
** - 
6/110 53/1001 
- - NC NC 
(6.2%) (2.5%) (0%) (5.4%) (5.29%) 
Song et al.,  
2014 ^ [33] 
64/1105 * 10/322 3/192 4/172 1/157 12/274 94/2222 4/1528 
- 
17 # 
(6.3–63) 
24% 
(10–62%) (5.8%) (3.1%) (1.6%) (2.3%) (0.6%) (4.4%) (4.23%) (0.26%) 
Norquist et al., 2016 [35] 
85/1498 3/77 0/58 1/70 0/16 9/196 98/1915 
- 
149/36276 14 
(8.2–23.8) 
NC 
(5.7%) (3.9%) (0%) (1.4%) (0%) (4.6%) (5.11%) (0.41%) 
Total 
211/3554 16/541 3/330 5/242 1/173 32/658 268/5498 4/1528 
- - - 
(5.93%) (2.95%) (0.91%) (2.0%) (0.57%) (4.86%) (4.87%) (0.26%) 
-: Not available, NC: Not calculated due to no controls or not described, ** Frequency of serous combined, * Frequency of HGS and serous undifferentiated, # Odds ratio (OR) for the matched controls 
analysis, a Risks based on all cases combined, b Mixed/Unknown includes some other histotypes, † Mucinous ovarian cancer cases were excluded, ^ Not screened for large genomic alterations. Bold: 
highlight info. 
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Furthermore, understanding the role of BRCA1/2 variants in ovarian cancer has allowed for the 
development of targeted therapies, namely PARP (poly[adenosine diphosphate–ribose] polymerase) 
inhibitors, which improve progression-free survival in selected women with ovarian cancer. 
Approximately 50% of HGS cases present defects in DNA repair mechanisms due to pathogenic 
variants in the homologous recombination deficiency (HRD) genes, such as BRCA1/2, or due to 
functional inactivation through methylation [40]. PARPi have shown highly efficacious activity 
particularly in women with platinum-sensitive disease carrying BRCA1/2 variants, or women with 
other homologous recombination deficiencies [41–43]. Improved activity has also been seen in 
women with recurrent disease regardless of their BRCA status [44]. As BRCA1/2 status affects clinical 
management of affected women, current guidelines recommend BRCA1/2 testing in all non-
mucinous ovarian cancer cases [39]. 
2.2. BRIP1 
The protein encoded by BRIP1 is part of the Fanconi anaemia group (FANCJ) and is involved in 
the repair of DNA double-strand breaks by homologous recombination. BRIP1 was described as a 
candidate risk gene by Walsh et al. that identified germline loss-of-function variants in 1% of ovarian 
cancer cases not selected for age or family history [34]. Pathogenic germline variants in BRIP1 are the 
most common mutation found in ovarian cancer after BRCA1/2 with a frequency of approximately 
1% of the EOC cases [11]. 
The contribution of germline protein truncating variants in BRIP1 have not yet been assessed in 
prospective studies. Ramus et al. described a relative risk associated with protein truncating variants 
in BRIP1 of 11.2 (95% CI 3.2–34.1), with an estimated cumulative risk of 5.8% (95% CI 3.6–9.1%) by 
the age of 80 years [11] (Table 2). The association between protein truncating variants in BRIP1 and 
risk of ovarian cancer has been confirmed in other analyses (associated risks ranged from 2.6 to 6.4 
[27–29,35,45]) (Table 2,3). The frequency of protein truncating variants in population-based studies, 
separated by ovarian cancer histotypes are given in Table 2, and the frequency in the other 
retrospective studies, mostly family studies or with women referred to clinical testing, are given in 
Table 3. Some of the studies in Table 3 have included predicted deleterious missense changes that 
cannot be separated from the totals, and these are indicated. 
Three studies have reported the frequency of protein truncating variants in BRIP1 by ovarian 
cancer histotype. Combining these data show that approximately 1.2% of HGS and END cases and 
0.8% of LGS cases had protein truncating variants in BRIP1 [11,34,35] (Table 2). No variants were 
observed in CCC and MUC, but the total number of cases examined were low. Additional studies are 
needed to further assess the contribution of germline protein truncating variants in BRIP1 in the 
ovarian cancer histotypes. 
Available data for BRIP1 consistently have shown an increased risk of ovarian cancer, with 
cumulative risk estimated to be approximately 6% by age of 80, and the National Comprehensive 
Cancer Network, USA, now recommends RRSO for women, starting from ages 45 to 50 [39]. 
2.3. RAD51C and RAD51D 
RAD51C and RAD51D are homologous recombination genes, which encode proteins that 
interact with BRCA1/2 and participate in the DNA repair process. Ovarian cancer risk attributed to 
protein truncating variants in RAD51C and RAD51D was first described by Meindl et al. in 2010 and 
Loveday et al. in 2011 [46,47]. 
Song et al. and Norquist et al. provided the frequency of protein truncating variants in the 
RAD51C/D genes in population-based studies by ovarian cancer histotypes [35,48] (Table 2). 
Combining their data, approximately 0.4–0.5% of HGS, END and CCC cases and 0.2% of LGS had 
protein truncating variants in RAD51C. For RAD51D, 0.5% of HGS cases and 0.9% of END cases had 
protein truncating variants. These variants were not detected in CCC, LGS, and MUC cases, although 
so far, the number of cases of these histotypes in the datasets are low. The frequency of deleterious 
variants in family-based studies that combined all EOC cases are given in Table 3. The estimated risk 
associated with RAD51C/D described in the two population-studies were OR 5.2 (95% CI 1.1–24) and 
Cancers 2020, 12, 3046 6 of 23 
 
3.4 (95% CI 1.5–7.6) for RAD51C and 12.0 (95% CI 1.5–90) and 10.9 (95% CI 4.6–26) for RAD51D (Table 
2) [35,48]. Three additional case-control studies which included only individuals referred to clinical 
testing estimated a risk of OR 4.9 (95%CI 3.0–8.0), OR 14.6 (95% CI 5.3 –29.5), and SRR 5.12 (95% CI 
3.7–6.9) for RAD51C. For RAD51D, associated risks were OR 4.78 (95% CI 2.1–10.7), OR 11.8 (95% CI 
1.1–40), and SRR 6.34 (95% CI 3.1–11.3) (Table 3) [26–28]. 
More recently, Yang et al. performed a study of 125 families with pathogenic variants in RAD51C 
and 60 families with pathogenic variants in RAD51D and confirmed an increased risk of ovarian 
cancer associated with pathogenic variants in both genes (RAD51C, RR 7.55, 95% CI 5.6–10.2 and 
RAD51D, RR 7.6, 95% CI 5.6–10.3) [10]. The cumulative risk of having ovarian cancer by age 80 was 
estimated to be 11% (95% CI 6–21%) for RAD51C and 13% (95% CI 7–23%) for RAD51D based on their 
segregation analysis [10] (Table 3). RAD51C/D were also shown to be associated with breast cancer 
with cumulative risk of 21% (95% CI 15–29%) and 20% (95% CI 14–28%) for these genes by the age of 
80 years, respectively [10]. 
There is no consensus about the EOC risk threshold for surgical prevention, although the 
acceptability of RRSO for women with a lifetime risk greater than 10% is well-established. It has been 
recently suggested that this threshold should be lower and was demonstrated that prophylactic 
surgery is cost-effective for women at lifetime risk of 5% [49–51]. Considering the current cumulative 
risk estimates for RAD51C and RAD51D, women carrying pathogenic variants in these genes could 
be offered preventive surgery starting from ages 45 to 50, once childbearing is complete. 
2.4. PALB2 
PALB2 is a confirmed breast cancer susceptibility gene with a cumulative risk estimated to be 
44% by 80 years [52], and therefore clinical testing for germline pathogenic variants in this gene is 
part of breast cancer standard of care. PALB2 is needed to recruit BRCA2 in the HR DNA repair 
pathway [53]. 
Initial analysis of 3227 EOC cases and 3444 matched-controls suggested that larger numbers of 
samples were required to determine if PALB2 was an ovarian cancer susceptibility gene (p 0.08) [11]. 
Evidence of risk association was observed in case-control analysis of 1915 EOC cases compared to 
publicly available controls with the OR estimated to be 4.4 (95% CI 2.1–9.1) [35]. Recently, PALB2 has 
been confirmed as a risk gene by targeted sequencing in 5123 HGS cases and 5202 controls, WES data 
from 829 cases and 913 controls, and genotyping data from an independent set of ~14,000 EOC cases 
and 29,000 controls [54]. The odds ratio was estimated to be 3.01 (95% CI 1.59–5.68) [54] (Table 2). 
Histotype data are only available from the first two studies, and combined show that 
approximately 0.4% of HGS cases had protein truncating variants in PALB2 (Table 2). A lower 
frequency was found for LGS (0.2%) and no variants were found in END and MUC. In contrast CCC 
cases had a frequency of 2.4%. The total number of non-HGS cases examined to date, particularly for 
CCC, is very low, thus larger numbers are needed to establish the true frequency of PALB2 
pathogenic variants in the rarer histotypes. 
An increased risk of ovarian cancer has recently been confirmed in a study of 976 individuals with 
protein truncating variants in PALB2 from 524 families, where complex segregation analysis adjusted 
for ascertainment was performed. The relative risk was estimated to be 2.91 (95% CI 1.4–6.0) [12] (Table 
3). Cumulative risks were estimated to be approximately 5% (95% CI 2–10%) by the age of 80 years in 
the family-based study [12] and 3.2% (95% CI 1.8–5.7%) by the same age in the case-control study 
previously described [54]. Discussions in the clinical community on whether or not these women should 
be eligible for prophylactic surgery are still ongoing. 
Yang et al. also showed that protein truncating variants in PALB2 were associated with increased 
risk of female and male breast cancer (RR 7.18 95% CI 5.8–8.8 and 7.34 95% CI 1.2–42.8, respectively) 
and pancreatic cancer (RR 2.37 95% CI 1.2–4.5) [12]. 
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Table 2. Frequency of germline protein truncating variants in BRIP1, RAD51C, RAD51D, and PALB2 in EOC histotypes, in cases from population studies. 
Gene Study 
Cases 
Carriers/Total (Frequency) 
Controls 
Carriers/Total (Frequency) Risk 
(95% CI) 
Cumulative Risk 
(95% CI) a 
HGS END CCC LGS MUC 
Mixed/ 
Unk b 
All EOC Matched Publicly Available 
BRIP1 
Walsh et al., 2011 [34] 
2/242 ** 1/23 0/17 
** - 
1/78 4/360 
- - NC NC 
(0.8%) (4.3%) (0%) (1.3%) (1.1%) 
Ramus et al., 2015 [11] 
26/2535 * 0/65 0/25 4/416 0/26 0/160 30/ 3227 3/3444 
- 
RR: 11.2 # 
(3.2–34.1) 
5.8% 
(3.6–9.1%) (1.0%) (0%) (0%) (0.9%) (0%) (0%) (0.92%) (0.09) 
Norquist et al., 2016 [35] 
22/1498 1/77 0/58 0/70 0/16 3/196 26/1915 
- 
60/36276 c OR: 6.4 
(3.8–10.6) 
NC 
(1.5%) (1.3%) (0%) (0%) (0%) (1.5%) (1.36%) (0.17%) 
Total 
50/4275 2/165 0/100 4/486 0/42 4/434 60/5502 3/3444 
- - - 
(1.17%) (1.21%) (0%) (0.82%) (0%) (0.9%) (1.1%) (0.09%) 
RAD51C 
Song et al., 2015 † [48] 
10/1806 * 1/383 1/225 1/405 0/166 1/444 14/3429 2/2772 
- 
OR: 5.2 # 
(1.1–24) 
5.2%¶ 
(1.1–22%) (0.6%) (0.3%) (0.4%) (0.2%) (0%) (0.2%) (0.40%) (0.07%) 
Norquist et al., 2016 † [35] 
7/1498 1/77 0/58 0/70 0/16 3/196 11/1915 
- 
39/36276 c OR: 3.4 
(1.5–7.6) 
NC 
(0.5%) (1.3%) (0%) (0%) (0%) (1.5%) (0.57%) (0.11%) 
Total 
17/3304 2/460 1/283 1/475 0/182 4/640 25/5344 2/2772 
- - - 
(0.51%) (0.43%) (0.35%) (0.21%) (0%) (0.62%) (0.47%) (0.07%) 
RAD51D 
Song et al., 2015 [48] 
9/1806 * 3/383 0/225 0/405 0/166 0/444 12/3429 1/2772 
- 
OR: 12 # 
(1.5–90) 
12%¶ 
(1.5–60%) (0.5%) (0.8%) (0%) (0%) (0%) (0%) (0.35%) (0.04%) 
Norquist et al., 2016 [35] 
7/1498 1/77 0/58 0/70 0/16 3/196 11/1915 
- 
14/36276 c OR: 10.9 
(4.6–26.0) 
NC 
(0.5%) (1.3%) (0%) (0%) (0%) (1.5%) (0.57%) (0.04%) 
Total 
16/3304 4/460 0/283 0/475 0/182 3/640 23/5344 1/2772 
- - - 
(0.48%) (0.87%) (0%) (0%) (0%) (0.47%) (0.43%) (0.04%) 
PALB2 
Ramus et al., 2015 [11] 
6/2535 * 0/65 1/25 1/416 0/26 1/160 9/3227 3/3444 
- NC NC 
(0.24%) (0%) (4%) (0.24%) (0%) (0.62%) (0.28%) (0.09%) 
Norquist et al., 2016 [35] 
9/1498 0/77 1/58 0/70 0/16 2/196 12/1915 
- 
39/36276 c OR: 4.4 
(2.1–9.1) 
NC 
(0.60%) (0%) (1.7%) (0%) (0%) (1.0%) (0.62%) (0.10%) 
Song et al., 2019 [54] 
18/5123 
- - - - - 
18/5123 6/5202 
- 
OR: 3.01 # 
(1.6–5.7) 
3.2% 
(1.8–5.7%) (0.35%) (0.35%) (0.12%) 
Total ^ 
15/4033 0/142 2/83 1/486 0/42 3/356 21/5142 3/3444 
- - - 
(0.37%) (0%) (2.4%) (0.2%) (0%) (0.84%) (0.41%) (0.09%) 
Abbreviations: RR—Relative risk; OR—odds ratio; SRR—Standardized risk ratio; -: Not available, NC: Not calculated due to no controls or not described, ** Frequency of serous combined, * Frequency of 
HGS and serous undifferentiated, # OR for the matched controls analysis, † Studies included one known deleterious missense variant [55], a Risks based on all cases combined, b Mixed/Unknown includes 
some other histotypes, c ExAC NFE-nonTCGA, ¶ Cumulative risks by age 70, ^ Total does not include Song et al., 2019 [54], study as extensive overlap with Ramus et al., 2015 [11]. Bold: highlight info. 
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Table 3. Frequency of germline pathogenic variants in BRIP1, RAD51C, RAD51D, and PALB2, in EOC cases from family history studies. 
Gene Study Type of Study 
Cases  
Carriers/Total 
(Frequency) 
Controls  
(Carriers/Total Frequency) Risk (95% CI) 
Cumulative 
Risk 
(95% CI) 
All EOC Matched Publicly Available 
BRIP1 
Lilyquist et al., 2017 ¶ [27] Clinical testing lab 58/6294 (0.92%) - ExAC SRR: 4.99 (3.8–6.4) NC 
Kurian et al., 2017 ¶ [26] Clinical testing lab 36/5020 (0.71%) 161/64,649 (0.24%) - OR: 2.62 (1.7–3.9) NC 
Castera et al., 2018 ¶ [28] Genetic counselling  21/4408 (0.48%) - 72/36,276 a (0.20%) OR: 3.77 (0.7–9.4) NC 
Suszynska et al., 2020 
[45] 
Meta-analysis ^ 200/22,494 (0.89%) - 
209/115,375 b 
(0.18%) 
OR: 4.94 (4.0–6.0) NC 
RAD51
C 
Meindl et al., 2010 [46] Family study 6/480 families - - NC NC 
Lilyquist et al., 2017 ¶ [27] Clinical testing lab 44/6294 (0.7%) - ExAC SRR: 5.12 (3.7–6.9) NC 
Kurian et al., 2017 ¶ [26] Clinical testing lab 32/5020 (0.6%) 72/64,649 - OR: 4.98 (3.0–8.0) NC 
Castera et al., 2018 ¶ [28] Genetic counselling 23/4309 (0.5%) - 43/36,276 a (0.12%) OR: 14.6 (5.3–29.5) NC 
Suszynska et al., 2019 
[29] 
Meta-analysis ^^ 21/3791 (0.6%) - - OR: 4.3 (2.5–7.5) NC 
Yang et al., 2020 [10] RAD51C families # 125 families - - RR: 7.55 (5.6–10.2) 11% (15–29%) 
Suszynska et al., 2020 
[45] 
Meta-analysis ^ 149/23,802 (0.62%) - 
130/115,475 b 
(0.11%) 
OR: 5.59 (4.4–7.0) NC 
RAD51
D 
Loveday et al., 2011 [47] Family study 8/911 families 1/1060 (0.09%) - RR: 6.30 (2.8–13.8) NC 
Lilyquist et al., 2017 ¶ [27] Clinical testing lab 11/5743 (0.2%) - ExAC SRR: 6.34 (3.1–11.3) NC 
Kurian et al., 2017 ¶ [26] Clinical testing lab 9/5020 (0.2%) 40/64,649 (0.06%) - OR: 4.78 (2.1–10.7) NC 
Castera et al., 2018 ¶ [28] Genetic counselling 9/4011 (0.2%) - 18/36,276 a (0.05%) OR: 11.8 (1.1–40) NC 
Suszynska et al., 2019 
[29] 
Meta-analysis ^^ 19/3258 (0.6%) - - OR: 11.6 (5.9–23) NC 
Yang et al., 2020 [10] RAD51D families # 60 families - - RR: 7.6 (5.6–10.3) 13% (7–23%) 
Suszynska et al., 2020 
[45] 
Meta-analysis ^ 94/22,787 (0.45%) - 72/120,688 b (0.06%) OR: 6.9 (5.1–9.4) NC 
PALB2 Yang et al., 2020 [12] PALB2 families # 524 families - - RR: 2.91 (1.4–6.0) 5% (2–10%) 
Abbreviations: RR —Relative risk; OR—odds ratio; SRR—Standardized risk ratio; PVs—Pathogenic variants; -: Not available, NC: Not calculated, a ExAC NFE non-TCGA, b gnomAD NFE non-TCGA, ¶ 
deleterious missense changes included, ^ [45] Overlapped with 6 studies included in this review; ^^ [29] Overlapped with 1 study included in this review; # Segregation analysis. Bold: highlight info. 
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2.5. Mismatch Repair (MMR) Genes 
Germline protein truncating and known deleterious missense variants in four MMR genes are 
associated with Lynch syndrome, which is an inherited disorder that increases the risk of many types 
of cancers including colon, endometrial, ovarian, pancreatic, small-bowel, and ureteric. In ovarian 
cancer cases from Lynch syndrome families, deleterious variants in the MMR genes were mostly seen 
in END and CCC cases and were more prevalent in the MSH2 and MSH6 genes [56]. This histotype-
specific characteristic has been confirmed by population-based cohorts of EOC [33,34]. 
Germline deleterious MMR gene variants in ovarian cancer cases appear to be very rare, which 
may partly be because they are associated with the rare histotypes of disease [33]. Three studies have 
described MMR gene mutation frequencies by ovarian cancer histotypes [33–35] (Table 4). 
We have combined the data across studies to provide an estimate of the frequency in these rarer 
histotypes (Table 4). Deleterious variants in these genes were more frequent in END and CCC cases 
than HGS. No variants were reported in MUC or LGS cases, although some studies combined HGS 
and LGS cases. Variants were more frequently found in MSH6 than the other genes, with CCC and 
END cases both having greater than 1% frequency. 
Five other case-control studies have investigated MMR frequencies between 2000 and 7500 EOC 
cases, four of which included data from commercial laboratories where clinical grade testing was 
performed in women with hereditary cancer risk [26–28,57], while another was a meta-analysis [29]. 
These studies have estimated the OR for mutation carriers of these genes. For MLH1 carriers the OR 
was 3 (95% CI, 1.47–6.59) [26], for MSH2 carriers, OR data from different studies ranged from 2 to 14 
[26–29], and for MSH6 carriers, ranged from 2 to 9 [26–29,57]. For the MMR genes combined, the OR 
was estimated to be 2.3 (95% CI, 0.83–8.2) with a cumulative risk of ovarian cancer by age 80 years of 
3.7% (95% CI, 1.4–13%) in cases from a population-based study [33]. 
A Lynch syndrome prospective study had estimated the cumulative risk of ovarian cancer as a 
unique disease to be 10% (95% CI 4.8–15.4%) for MLH1 carriers by the age of 75 years, 17% (95% CI 5.7–
28.0%) for MSH2 carriers, and 13% (95% CI 0.1–31.2%) for MSH6 carriers [13]. The risk in the different 
EOC histotypes was not reported [13], although it is known that they are mostly seen in END and CCC 
cases. 
The cumulative risk of endometrial cancer by the age of 75 years was estimated to be 43% (95% 
CI 33.1–52.3%), 57% (95% CI 41.8–71.6%), and 46% (95% CI 27.3–65.0%) for MLH1, MSH2, and MSH6 
carriers, respectively [13]. Due to the increased risk of both ovarian and endometrial cancer in women 
with Lynch syndrome, discussion about RRSO with hysterectomy is recommended. MMR carriers 
from these Lynch syndrome families were also reported to have an increased risk of colorectal, upper 
gastrointestinal, urinary tract, prostate, and brain cancers [13]. 
3. Missense Variants in Confirmed Susceptibility Genes 
Protein truncating variants have been classified as deleterious, however a relatively large 
number of missense variants, including some rare predicted pathogenic missense variants have also 
been identified in these genes. Determining if any of these missense variants are also pathogenic is 
important for patient management and risk prediction in families. 
3.1. BRCA1/2 and MMR Genes 
Over many years, due to efforts of commercial labs, independent research groups, and large 
consortia, many missense variants of unknown significance (VUS) or unclassified variants (UV) have 
been reclassified as either pathogenic or benign. However, there are still many variants that remain 
unclassified. Large-scale consortia efforts, such as the Evidence-based Network for the Interpretation 
of Germline Mutant Alleles (ENIGMA) are in the process of investigating and classifying these 
variants in the BRCA1/2 genes and the interpretation of the results of genetic testing for reporting and 
counselling [58]. 
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Table 4. Frequency of germline pathogenic variants in the mismatch repair (MMR) genes in EOC histotypes, in cases from population studies. 
Gene Study 
Cases 
Carriers/Total 
(Frequency) 
Controls 
Carriers/Total 
(Frequency) 
HGS END CCC LGS MUC 
Mixed/ 
Unk a 
All EOC Matched 
MLH1 
Song et al., 2014 [33] 
0/1105 * 0/322 1/192 0/172 0/157 0/274 1/2222 2/1528 
(0%) (0%) (0.52%) (0%) (0%) (0%) (0.04%) (0.13%) 
Norquist et al., 2016 [35] 
0/1498 0/77 0/58 0/70 0/16 1/196 b 1/1915 
- 
(0%) (0%) (0%) (0%) (0%) (0.51%) (0.05%) 
Total 
0/2603 0/399 1/250 0/242 0/173 1/470 2/4137 2/1528 
(0%) (0%) (0.40%) (0%) (0%) (0.21%) (0.04%) (0.13%) 
MSH2 
Song et al., 2014 [33] 
1/1105 * 0/322 1/192 0/172 0/157 0/274 2/2222 0/1528 
(0.09%) (0%) (0.52%) (0%) (0%) (0%) (0.09%) (0%) 
Total 
1/1105 0/322 1/192 0/172 0/157 0/274 2/2222 0/1528 
(0.09%) (0%) (0.52%) (0%) (0%) (0%) (0.09%) (0%) 
MSH6 
Walsh et al., 2011 [34] 
0/242 ** 2/23 0/17 
** - 
0/78 2/360 
- 
(0%) (8.7%) (0%) (0%) (0.55%) 
Song et al., 2014 [33] 
4/1105 * 2/322 3/192 0/172 0/157 0/274 9/2222 1/1528 
(0.36%) (0.62%) (1.56%) (0%) (0%) (0%) (0.40%) (0.06%) 
Norquist et al., 2016 [35] 
1/1498 2/77 0/58 0/70 0/16 0/196 3/1915 
- 
(0.06%) (2.59%) (0%) (0%) (0%) (0%) (0.15%) 
Total 
5/2845 6/422 3/267 0/242 0/173 0/548 14/4497 1/1528 
(0.17%) (1.42%) (1.12%) (0%) (0%) (0%) (0.31%) (0.06%) 
PMS2 
Song et al., 2014 [33] 
0/1105 * 1/322 0/192 0/172 0/157 0/274 1/2222 0/1528 
(0%) (0.31%) (0%) (0%) (0.6%) (0%) (0.04%) (0%) 
Norquist et al., 2016 [35] 
4/1498 0/77 0/58 0/70 0/16 0/196 4/1915 
- 
(0.3%) (0%) (0%) (0%) (0%) (0%) (0.20%) 
Total 
4/2603 1/399 0/250 0/242 0/173 0/470 5/4137 0/1528 
(0.15%) (0.25%) (0%) (0%) (0%) (0%) (0.12%) (0%) 
All 4 
genes 
Total $ 
10/2845 7/422 5/267 0/242 0/173 1/548 23/4497 3/1528 
(0.35%) (1.65%) (1.87%) (0%) (0%) (0.18%) (0.51%) (0.19%) 
-: Not available, ** serous combined, * HGS and serous undifferentiated, a Mixed/Unknown includes some other histotypes, b MLH1 variant found in carcinosarcoma, $ Totals did not include overlapped 
studies. Bold: highlight info. 
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To date, the National Institutes of Health (NIH) repository, ClinVar, has reported approximately 
7000 pathogenic or likely pathogenic variants and 7400 VUS in BRCA1/2 genes (mostly missense 
changes, but also in-frame deletions and insertions, and intronic and exonic variants that may affect 
splicing efficiency) [59]. The same clinical challenge occurs in patients with variants in the MMR 
genes, approximately 30% of all variants are classified as VUS [60]. 
Individual studies may include analysis of missense variants using bioinformatic tools such as 
SIFT [61], PolyPhen-2 [62], and Provean [63] to predict the functional effect of variants. Association 
between predicted deleterious rare missense variants and ovarian cancer risk can be assessed using 
burden tests, such as the rare admixture maximum likelihood test (RAML), that accounts for 
differences in risk of each associated variant [64]. Song et al. have performed this type of analysis in 
131 predicted deleterious missense variants in BRCA1/2 and the MMR genes (MLH1, MSH2, MSH6, 
and PMS2) and found little evidence for ovarian cancer risk association between these variants in any 
of the six genes [33]. 
3.2. BRIP1, RAD51C/D and PALB2 
Missense variants in the moderate-risk genes recently confirmed as susceptibility genes in 
ovarian cancer need further investigation to determine if any are likely to be pathogenic. Some studies 
have included predicted deleterious missense variants in estimating mutation frequencies. 
Ramus et al. used SIFT, PolyPhen-2, and Provean scores to predict if uncommon (minor allele 
frequency (MAF) < 1%) and rare (MAF < 0.1%) missense variants were potentially deleterious and 
identified 35 for BRIP1 and 26 in PALB2. They performed the RAML burden test and found an 
increased risk association for uncommon and rare missense variants in BRIP1, but not for PALB2 
[11,54]. 
In RAD51C/D, Song et al. performed the RAML test for 28 rare predicted deleterious missense 
variants (12 in RAD51C and 16 in RAD51D) [48]. Evidence for an association of rare predicted 
deleterious missense variants with an increased risk of ovarian cancer was observed in both genes 
[48] (Table 5). 
The data from the RAML burden test suggest that some of the predicted deleterious missense 
variants in BRIP1, RAD51C, and RAD51D likely increase disease risk, but it does not indicate how 
many or which ones. There is no evidence for specific missense variants. 
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Table 5. Predicted deleterious missense variants in known moderate risk genes for EOC. 
Genes Study 
Cases 
Del Missense/Total 
(Frequency) 
Predicted Deleterious 
Evidence of Risk 
from RAML 
BRIP1 
Ramus et al., 2015 [11] 
35/3227 a 
(1.1%) 
SIFT, PolyPhen-2 and Provean 
Yes 
(All EOC, but stronger in HGS) 
Suszynska et al., 2020 [45] 2 */22494 Described in ClinVar - 
RAD51C 
Song et al., 2015 [11] 
12/3429 b 
(0.32%) 
SIFT, PolyPhen-2 and Provean 
Yes 
(All EOC, but stronger in HGS) 
Lilyquist et al., 2017 [27] 2 $/6294 Described in ClinVar - 
Norquist et al., 2016 [35] 1 #/1915 c Functional assay [65] - 
Suszynska et al., 2020 [45] 3 ^/22,494 Described in ClinVar - 
RAD51D 
Song et al., 2015 [11] 
16/3429 
(0.46%) 
SIFT, PolyPhen-2 and Provean 
Yes 
(Only in HGS) 
Suszynska et al., 2020 [45] 1 ¶/22,494 Described in ClinVar - 
PALB2 
Ramus et al., 2015 [11] 
26/3227 
(0.80%) 
SIFT, PolyPhen-2 and Provean 
No 
 
Song et al., 2019 [54] 
40/5123 a 
(0.78%) 
SIFT, PolyPhen-2 and Provean No 
-: Not available, a All variants reported in HGS, b One variant found in LGS – (histotype not available for the other variants), c Variant found in a serous carcinoma. ClinVar reported variants: * p.Gln169 = and 
p.Ala349Pro; $ p.C135Y and p.L138F; # p.Q143R; ^ p.Cys135Tyr, p.Cys135Ser and p.Leu138Phe; ¶ p.Ser207Leu. 
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4. Deleterious Variants in Other Proposed Susceptibility Genes 
4.1. FANCM 
FANCM is part of the Fanconi anemia group together with BRCA2, BRIP1 and PALB2 (also 
known as FANCD1, FANCJ, and FANCN). A case-control study was performed by Dicks et al. where 
FANCM targeted sequencing was performed in 3107 HGS cases, 1491 cases of other histotypes, and 
3368 unaffected matched controls [66]. A significantly higher frequency of protein truncating variants 
was found in the HGS cases compared to the controls (p 0.008) and no evidence of association was 
observed with other histotypes (p 0.82) [66]. The relative risk for HGS was estimated to be 2.5 (95% 
CI 1.3–5) with lifetime average risk of 3.8% (80% CI 2.2–4.5%) [66]. Lifetime risk was increased when 
known ovarian cancer risk factors such as common risk alleles and lifestyle factors were taken into 
account (4.6% (80% CI 3.1–7.0%) and 5.2% (80% CI 3.4–7.8%), respectively) [66]. Additionally, the 
RAML test was performed for 243 uncommon predicted deleterious missense variants (effect given 
by at least two of the three function prediction programs Polyphen-2, Provean, and SIFT), but there 
was no difference in the frequency of these variants in cases compared to controls [66]. 
Although this study had shown evidence of association between germline protein truncating 
variants in FANCM and moderate increase in risk of HGS ovarian cancer, larger and prospective 
studies are still needed to confirm this. 
4.2. ATM 
ATM is a candidate ovarian cancer susceptibility gene due to its role in breast [67] and pancreatic 
cancer [68]. Germline heterozygous pathogenic ATM variants are associated with fivefold higher risk 
of breast cancer by the age of 50 years [67] and some rare variants have been shown to have 
penetrance as high as the BRCA2 gene [69]. 
In ovarian cancer, case-control studies mainly enriched for a family history of breast or ovarian 
cancer, have suggested that pathogenic or likely pathogenic variants in ATM might be associated 
with moderate increased risk (OR 1.69, 95% CI 1.2–2.4 [26]; Standardized risk ratio (SRR) 2.25, 95% 
CI 1.7–3 [27]; OR 1.97, 95% CI 1.3–3 [29]; OR 2.4, 95% CI 1.2–4.7 [35]; OR 2.85, 95% CI 1.3–6.3 [57]), 
however the cumulative lifetime risk has been estimated to be lower than 3%. 
4.3. BARD1 and NBN 
The BARD1 and NBN genes were included in breast/ovarian cancer genetic panel tests, due to 
their breast cancer risk, despite the ovarian cancer risk for deleterious variants in these genes being 
unknown. The BARD1 encoded protein interacts closely with the BRCA1 protein due to sharing the 
N-terminal RING finger and the BRCA1 C-terminal domains. Interaction between these genes affects 
double-strand break repair and apoptosis suggesting that this protein may play an important role in 
BRCA1 tumour suppression [70]. Consequently, BARD1 was considered a potential candidate 
susceptibility gene for ovarian cancer. However, Ramus et al. found no significant differences in 
BARD1 deleterious variants frequency in a cohort of ~3200 ovarian cancer cases compared with ~3400 
matched-controls (p 0.39) [11]. Several additional case-control studies confirmed that no evidence of 
association was observed between ovarian cancer risk and pathogenic variants in BARD1 (OR 0.59, 
95% CI 0.21–1.68 [26]; SSR 1.28, 95% CI 0.55–2.51 [27]; OR 1.4, 95% CI 0.7–2.9 [29]). A moderate 
increase in breast cancer risk has been suggested but more evidence is needed to validate these 
findings [70,71]. 
The NBN encoded protein interacts with MRE11A and RAD50 encoded proteins as a large 
complex, which interacts with the protein produced by the ATM gene. These combined proteins have 
an important role in identifying broken strands of DNA and repairing it. Due to its essential function 
in the DNA repair pathway and because this gene is commercially available in gene testing panels 
for ovarian cancer, case-controls studies have examined if they are susceptibility genes. However, 
most studies have not found a higher frequency of pathogenic variants in NBN, MRE11A, or RAD50 
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in cases compared to controls (NBN: p 0.61 [11] and 0.09 [35]; MRE11A: p 1.0 [35]; RAD50: p 0.63 [35]) 
and therefore no evidence of association with risk was observed in any of these 3 genes. 
4.4. CHECK2 
Germline pathogenic variants in CHECK2 (a cell cycle checkpoint regulator) are associated with 
an increased risk of breast cancer [72] and CHECK2 was proposed to be a candidate gene for ovarian 
cancer risk on that basis. A prospective study had shown that in estrogen receptor–positive breast 
cancer, CHEK2*1100delC heterozygosity was associated with increased risk of early death, breast 
cancer–specific death, and risk of a second breast cancer [72]. However, numerous retrospective case-
control studies did not find an association between pathogenic variants in CHECK2 and an increased 
risk of ovarian cancer [26,27,35]. 
4.5. Other Genes 
TP53 was suggested as a potential candidate susceptibility gene for ovarian cancer from a case 
only study [34] and from a whole-exome sequencing analysis where protein truncating variants were 
identified at a greater frequency in ovarian cancer cases compared to publicly available controls (OR 
18.5; 95% CI, 2.6–808.1) [34,57]. This gene has not been validated in other targeted sequencing and 
WES studies [26,35]. 
Other candidate genes selected for targeted sequencing validation in cases and controls have 
shown weak evidence of association with ovarian cancer risk for protein truncating variants in POLK, 
SLX4 (also known as FANCP), and FBXO10, but further studies are required to confirm this [54]. 
Several Fanconi Anaemia genes (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCG, FANCI, and 
FANCL) have been tested in these case-control studies but a risk association has not been detected 
[54]. A large number of other genes have been examined and not been shown to be ovarian cancer 
risk genes [48,57,66]. 
5. Discussion 
We have presented a comprehensive review of the contribution of rare genetic variants to 
ovarian cancer, with a focus on the relationship between genetic variation and ovarian cancer 
histotypes, using data mostly only presented as supplementary in the original papers. 
For BRCA1/2, deleterious germline variants are more common in HGS (8% for BRCA1 and 6% 
for BRCA2), but there is a significant frequency of variants in END (3% for both genes), CCC (3% for 
BRCA1 and 1% for BRCA2), and LGS (3% for BRCA1 and 2% for BRCA2) patients. Consequently, the 
current guidelines recommend BRCA1/2 testing in all non-mucinous ovarian cancer cases. For the 
MMR genes, the frequency of deleterious germline variants is higher in END and CCC patients, with 
variants in MSH6 being more common than variants in MLH1, MSH2, and PMS2 (greater than 1% in 
MSH6 and approximately or less than 0.5% in MLH1/MSH2/PMS2). For BRIP1, the frequency of 
protein truncating variants seems to be similar for HGS and END (approximately 1.2%), but slightly 
lower for LGS cases (0.8%). For RAD51C, a slightly higher frequency of variants in the HGS cases is 
observed (0.5%), and frequencies range from 0.2 to 0.4% in END, CCC, and LGS. No variants in MUC 
were found. In contrast, a higher frequency of protein truncating variants in END cases is seen for 
RAD51D (0.9%), compared to the HGS cases (0.5%). No variants were detected in CCC, LGS, or MUC. 
A higher frequency of protein truncating variants in CCC is seen in PALB2, compared to 0.4% in HGS 
and 0.2% in LGS. However, larger numbers of the non-HGS cases are needed to confirm these 
frequencies especially in the moderate risk genes that have been recently confirmed as susceptibility 
genes for ovarian cancer. 
The role of individual missense variants in the known ovarian cancer genes is not yet known. 
Work by the ENIGMA consortium is underway to identify deleterious missense variants in BRCA1 
and BRCA2, and ongoing efforts will be required for other genes [58]. 
The frequency of large genomic alternations (insertions, deletions, and rearrangements) have 
been examined in BRCA1/2 and the MMR genes [17,73]. These types of changes make up 8–40% of 
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BRCA1 mutations, depending on the population [17]. We do not yet know how frequent they are in 
the BRIP1, RAD51C, RAD51D, and PALB2 genes, and this could affect prevalence estimates. These 
types of changes cannot be detected with the methods currently used for targeted sequencing in 
clinical panel testing. 
As outcomes in ovarian cancer are linked to its stage at diagnosis, the ability to identify women 
at risk earlier or before diagnosis has important clinical implications. The use of multigene panel 
testing has allowed women to be tested for multiple genetic variants associated with increased cancer 
risk, enabling personalised risk estimates to be developed [74,75]. While screening for ovarian cancer 
has not been shown to reduce mortality, RRSO can be offered to women at a sufficiently high risk of 
developing ovarian cancer [4,5]. 
There has been some debate as to what level of lifetime cancer risk justifies prophylactic surgical 
intervention. Traditionally, a threshold of greater than 10% lifetime ovarian cancer risk was used, 
allowing for RRSO in women carrying BRCA1, BRCA2, or mismatch repair gene mutations, which 
confer lifetime ovarian cancer risk well in excess of 10% [76]. The more recent discovery of moderate 
penetrance genes has prompted formal studies into risk thresholds for invention, and recent analyses 
have suggested that offering RRSO to women with a lifetime risk as low as 4–5% can be cost-effective 
[50]. On that basis, women carrying variants in BRIP1, RAD51C, and RAD51D may also be offered 
RRSO [77,78]. 
The best approach to managing patients with genetic variants that do not sufficiently increase 
ovarian cancer risk to justify RRSO but increase risk to higher than that of the general population is 
not yet known. While it is plausible that targeting these women for screening may allow for detection 
of cancers at an earlier stage, this has not been studied. Studies investigating the impact of ovarian 
cancer screening using ultrasonographic and biochemical methods in both the general population, 
and high-risk groups (greater than 10% risk on the basis of family history or presence of genetic 
variants) have been associated with stage-shift, but have not been shown to significantly reduce 
mortality [5,79]. 
Genetic testing is fraught with ethical, legal, and psychosocial implications for patients, and the 
rate of advancement in our understanding of cancer genetics often outstrips our ability to use 
information in the clinic [80,81]. It is important to note that genetic susceptibility to EOC cancer does 
not exist in isolation, and variants conferring increased ovarian cancer risk also often increase the risk 
of developing other cancers—most notably breast cancer in BRCA1 and BRCA2, and colon cancer in 
Lynch syndrome. Furthermore, breast and ovarian cancer genes are often combined into a single 
panel test, potentially uncovering variants in genes for which pathogenicity is disputed. As an 
example, PALB2 is associated with a lifetime breast cancer risk of 53%, but also lifetime risks of 5% 
and 2–3% for ovarian and pancreatic malignancies, respectively [12]. While a 53% lifetime breast 
cancer risk is clearly clinically actionable, the risk of ovarian and pancreatic cancers associated with 
PALB2 exists in an area of clinical uncertainty. The opposite is seen for deleterious variants in BRIP1, 
with an increased risk of ovarian cancer but no increase in breast cancer risk. For these reasons, all 
women undergoing genetic testing for familial susceptibility to ovarian cancer should receive 
appropriate pre- and post-test counselling, and follow-up with relevant clinical services. Genetic 
information should be applied cautiously in the clinic, after careful evaluation of the available 
literature, as some genes included on so called “ovarian cancer” panel tests have now been shown 
not to increase ovarian cancer risk [82,83] (Table 6). The risks of ovarian and breast cancer for genes 
in the double-strand DNA break repair pathway are shown in Figure 1. 
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Table 6. Summary of the frequency of deleterious variants by EOC histotype for each homologous recombination (HR) gene and the MMR genes, and a comparison of risk 
and clinical management for ovarian and breast cancer patients. 
Genes 
Frequency (%) Risk Est. ^ Risk Level Clinical Management $ 
HG
S 
END CCC LGS MUC EOC BC EOC BC EOC BC 
BRCA1 7.8 2.9 3.6 3.7 <1 60 72% * Very high Very high RRSO age 35 to 45 
PARPi 
RRM age 25 to 40 
BRCA2 5.9 2.9 <1 2 <1 17 69% * High Very high 
MMR <1 1.6 1.9 0 0 2.3 - Mod None RRSO with hysterectomy for LS No increased risk 
BRIP1 1.2 1.2 0 <1 0 11.2 - Mod None 
RRSO age 45 to 50 
no consensus 
Insufficient evidence RAD51C <1 <1 <1 <1 0 5.2 1.9 Mod None 
RAD51D <1 <1 0 0 0 12 1.8 Mod None 
PALB2 <1 0 2.4 <1 0 3.0 7.2 Low Mod Insufficient evidence 
Annual 
mammography/breast 
MRI age 30 
no consensus 
TP53 Insufficient data Insuf Insuf Low Mod Insufficient evidence Insufficient evidence 
CHEK2 No increased risk - 3.0 None Low 
No increased risk 
Annual 
mammography/breast 
MRI age 40 
no consensus 
ATM No increased risk - 2.8 None Low 
NBN No increased risk - 2.7 None Low 
RAD50 No increased risk - Insuf None Low 
No increased risk Insufficient evidence 
MRE11A No increased risk - Insuf None Low 
Abbreviations: BC—breast cancer; RRM—Risk-reducing mastectomy; LS—Lynch Syndrome; MRI—Magnetic Resonance Imaging; Insuf—Insufficient. ^ From tables 1,2,4. EOC BRCA1/2 from ref [33], MMR 
from ref [33], BRIP1 from ref [11], RAD51C/D from ref [48], PALB2 from ref [54]. BC BRCA1/2 from ref [9], RAD51C/D from ref [10], PALB2 from ref [12], CHEK2/ATM/NBN from ref [84]. $ BRCA1/2 from 
refs [39,85], MMR from ref [13], BRIP1/RAD51C/D from ref [49], PALB2/CHEK2/ATM/NBN from refs [77,84]. * Cumulative risk data by the age of 80. 
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Figure 1. Susceptibility genes present in the double-strand DNA break repair pathway for ovarian 
and breast cancer and its different correspondent risks levels in each disease. 
Current testing guidelines do not recommend population-based genetic testing for ovarian 
cancer, however population-based testing approaches may be effective in groups with a small 
number of common founder mutations such as the three BRCA1/2 variants in Ashkenazi Jews [86,87]. 
With the decreasing costs of sequencing methods, these approaches may also become cost effective 
in other populations. Population-based genetic testing has many issues, including cultural and 
psychosocial, that need to be investigated [87]. The majority of the genetic studies in ovarian cancer 
have been performed in white populations, and work on other ethnic groups is ongoing [88]. 
Identifying ovarian cancer genes has translated to novel therapeutic options for patients. PARP 
inhibitors, which target double-stranded DNA repair in cells with deficient homologous 
recombination, including cells with dysfunctional BRCA DNA repair pathways, have been shown to 
improve progression free survival (PFS) in serous and endometrioid ovarian cancers [89–92]. The 
impact of PARP inhibitors on PFS is most dramatic in patients with mutations in BRCA1 and BRCA2, 
but can also benefit women without BRCA mutations if they are found to have deficiencies in 
homologous recombination, such as variants in the DNA repair genes discussed above [92]. 
However, improvements in PFS do not necessarily translate to improved overall survival, and the 
impact of PARP inhibitors on the overall survival endpoint has not yet been reported [92]. 
To date, ovarian cancer has largely been treated as a single entity. However, as outlined above, 
the five main histotypes of epithelial ovarian cancer appear to be characterised by distinct genetic 
mutations. The tumours also have different molecular profiles, and patients have different treatment 
responses [93]. Therefore, it has become increasingly clear that ovarian cancer represents not just a 
single disease but encompasses a number of distinct cancers. Most of our understanding of ovarian 
cancer genes relates to high-grade serous tumours, as they represent the majority of ovarian cancers. 
Identifying genetic variants contributing to non-serous ovarian cancers has posed an ongoing 
challenge for researchers, as finding rare variants for rare cancers requires studies with sample sizes 
that are not yet feasible. 
Despite significant advancements in our understanding of the genetic epidemiology of ovarian 
cancer, the known ovarian cancer risk variants explain less than half of the excess familial risk for 
ovarian cancer [8]. Efforts to identify novel genetic variants associated with ovarian cancer are 
ongoing. The discovery of new genetic variants should be accompanied by efforts to accurately 
quantify the exact magnitude of increased risk associated with that variant. Case-control studies, the 
most commonly used study design in gene discovery, are only able to generate relative risks, from 
which absolute risks are extrapolated. 
Prospective population-based studies, which have been used to provide gold-standard estimates 
of lifetime cancer risk in BRCA1, BRCA2, and the mismatch repair genes, would provide more 
accurate risk estimates for moderate penetrance ovarian cancer genes, but are costly, and require 
long-term investment. Segregation analysis from large international consortia has been used to 
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calculate ovarian cancer risks in RAD51C, RAD51D, and PALB2, and could be applied to other 
moderate risk ovarian cancer genes [10,12]. 
Genetic association studies, by their design, are unable to establish a causal relationship between 
germline variant status and cancer phenotype. The discovery of novel ovarian cancer risk genes 
should be followed-up by further efforts to characterise the functional mechanisms by which they 
contribute to cancer development and identify potential therapeutic targets. 
6. Conclusions 
Ovarian cancer is the most lethal gynaecological malignancy, and an improved understanding 
of the contribution of rare genetic variants to the development of ovarian cancer allows for better 
clinical management of at-risk women. Based on the best available evidence, variants in BRCA1, 
BRCA2, BRIP1, RAD51C, RAD51D, and the mismatch repair genes confer ovarian cancer risks that 
warrant the consideration of risk-reducing surgery. The best approach for managing women with 
deleterious variants in ovarian cancer genes that do not warrant prophylactic surgery requires further 
investigation. 
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